Targeted therapy in pediatric malignancies treatment: Pediatric Oncology and Haematology Research Institute experience


Cite item

Full Text

Abstract

Actually targeted drugs became a therapeutic component for adult patients with malignancies and merge into clinical therapeutic recommendations. Targeted drugs in pediatric oncology had been using for 10-15 years and this experience under systematization and analysis. In the current issue 12-year experience of targeted therapy of Pediatric Oncology and Haematology Research Institute of N.N.Blokhin National Cancer Research Center is presented. Authors estimated efficacy and toxicity of rituximab, bortezomib, sorafenib and everolimus in 108 patients with advanced stages of mature B-cell non-Hodgkins lymphomas (B-NHL), relapsed/refractory acute lymphoblastic leukemia (ALL) and refractory osteosarcoma. Rituximab plus standard chemotherapy of advanced stages of B-NHL increased 10-years event-free survival up to 93.8±3%. Bortezomib plus anti-relapsed chemotherapy protocol (COG AALL07P1) reached minimal residual disease - negative status in 64.3% patients, but relapse-free survival was 24.5±19.4% (median 28±3.3 months). Sorafenib and everolimus were used for refractory osteosarcoma treatment, response rate was 100%, progression-free survival more than 6 months was 46% (median follow up 7±1.2 months). Toxicity profile was acceptable.Our data demonstrate a fact of significant improvement of advanced stages B-NHL treatment results by rituximab use, but relapsed/refractory ALL and osteosarcoma need treatment improvement.

About the authors

T T Valiev

Pediatric Oncology and Haematology Research Institute of N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation

Email: timurvaliev@mail.ru
д-р мед. наук, ст. науч. сотр. отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ «РОНЦ им. Н.Н.Блохина» 127273, Russian Federation, Moscow, Kashirskoe sh., d. 24

A S Levashov

Pediatric Oncology and Haematology Research Institute of N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation

науч. сотр. отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии «ФГБУ РОНЦ им. Н.Н.Блохина» 127273, Russian Federation, Moscow, Kashirskoe sh., d. 24

N A Batmanova

Pediatric Oncology and Haematology Research Institute of N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation

врач отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ «РОНЦ им. Н.Н.Блохина» 127273, Russian Federation, Moscow, Kashirskoe sh., d. 24

E R Senzhapova

Pediatric Oncology and Haematology Research Institute of N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation

науч. сотр. отд-ния опухолей опорно-двигательного аппарата НИИ детской онкологии и гематологии ФГБУ «РОНЦ им. Н.Н.Блохина» 127273, Russian Federation, Moscow, Kashirskoe sh., d. 24

K A Turupaev

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

Email: kir-turupaev@yandex.ru
студент 5-го курса лечебного фак-та ФГБОУ ВО «МГМСУ им. А.И.Евдокимова» 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

U V Tomchik

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: vip_uv@mail.ru
студентка 5-го курса педиатрического фак-та ФГБОУ ВО «РНИМУ им. Н.И.Пирогова» 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

G A Aleskerova

Pediatric Oncology and Haematology Research Institute of N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation

аспирантка отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ «РОНЦ им. Н.Н.Блохина» 127273, Russian Federation, Moscow, Kashirskoe sh., d. 24

References

  1. Программное лечение заболеваний системы крови. Под ред. В.Г.Савченко. М., 2012.
  2. Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). М., 2010.
  3. Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И.Переводчиковой. М., 2011.
  4. Состояние онкологической помощи населению России в 2015 году. Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М., 2016.
  5. Валиев Т.Т., Левашов А.С., Сенжапова Э.Р. Таргетные препараты в детской онкологии. Онкопедиатрия. 2016; 3 (1): 8-15.
  6. Goldman S, Smith L, Anderson J.R et al. Outcome of advanced stage (III/IV) intermediate - risk patients with mature B-NHL using rituximab plus FAB group B4 chemotherapy: A Children's Oncology Group report. Brit J Haematol 2012; 159 (Suppl.) 1 (24).
  7. Osumi T, Mori T, Fujita N et al. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer 2016; 63 (10):1794-9.
  8. Minard-Colin V, Auperin A, Jourdain A et al. Outcome of relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in the Rituximab Era: A study of the Société Française des Cancers de l'Enfant. Brit J Haematol 2015; 171 Suppl. 1 (6).
  9. Awasthi A, Ayello J, van de Ven C et al. Obinutuzumab versus rituximab significantly enhances apoptosis and ADCC in vitro and overall survival in vivo of rituximab sensitive/resistant Burkitt Lymphoma (BL). Brit J Haematol 2015; 171 Suppl. 1 (83).
  10. Corongiu F, Mura R, Pillon M. Late effects of Rituximab in combination with chemotherapy in patients with Bcell NHL or BAL. Brit J Haematol 2015; 171 Suppl. 1 (66).
  11. Алескерова Г.А, Шервашидзе М.А., Попа А.В. и др. Результаты лечения острого лимфобластного лейкоза у детей по протоколу ALL IC-BFM 2002. Онкопедиатрия. 2016; 3 (4): 302-8.
  12. Gaynon P.S. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 2005; 131: 579-87.
  13. Koh K.N, Im H.J, Kim H et al. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study. J Korean Med Sci 2017; 32 (4): 642-9. doi: 10.3346/jkms.2017.32.4.642.
  14. Bertaina A, Vinti L, Strocchio L et al. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol 2017; 176 (4): 629-36.
  15. Junk S, Cario G, Wittner N et al. Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines. Klin Padiatr 2015; 227 (3): 123-30.
  16. Franz D.N, Belousova E, Sparagana S et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo - controlled phase 3 trial. Lancet 2013; 381 (9861): 125-32.
  17. Fouladi M, Laningham F, Wu J. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007; 25 (30): 4806-12.
  18. Woessmann W, Seideman K, Mann G et al. The impact of methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005; 105: 948-58.
  19. National Cancer Institute - Common Terminology Criteria for Adverse Events. CTCAE 2009. Version 4. https://www.calgb.org/Public/meetings/presentations/2009/ summer_ group/ cra_committee/04_ CTCAE-Chen_062009.pdf
  20. Miyamoto K.I, Kobayashi Y, Maeshima A.M et al. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Int J Hematol 2016; 103 (6): 693-702.
  21. Swerdlow S.H, Campo E, Lee Harris N et al. WHO Classification of Tumours of Haematopoetic and Lymphoid tissues. 4th Еd. International Agency for Research on Cancer. Lyon 2008; р. 439.
  22. Самочатова Е.В., Шелихова Л.Н., Белогурова М.Б. и др. Комбинированная химиоиммунотерапия больных неходжкинскими лимфомами из зрелых В-клеток возрастной группы до 18 лет: результаты многоцентрового исследования НХЛ 2004м с применением ритуксимаба и модифицированного протокола В-НХЛ БФМ 90. Онкогематология. 2009; 3: 4-14.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies